MORRISVILLE, N.C.--(BUSINESS WIRE)--Dr. Andrew Finn, Executive Vice President of Product Development for BioDelivery Sciences International, Inc. (Nasdaq:BDSI), will present at the American Society of Clinical Pharmacology and Therapeutics 2007 Annual Meeting on Thursday, March 22nd 2007 at the Anaheim Marriott Hotel in Anaheim, California. Beginning at 2:30 PM PDT, Dr. Finn will participate in a panel discussion entitled “Novel routes of drug delivery: eye, cheek, nose and lung” to discuss the potential benefits of buccal drug delivery (between the gum and cheek), highlighting BDSI’s Phase III BEMA™ Fentanyl product for the treatment of breakthrough cancer pain.
